Previous 10 | Next 10 |
Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire NEWARK, Calif. , June 18, 2021 /PRNewswire/ -- Protagonist Therapeutics, In...
Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock PR Newswire NEWARK, Calif., June 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announce...
Protagonist Therapeutics (PTGX) commences $100M public offering of shares. Underwriter's 30-day option to purchase up to an additional 15% shares.Shares drop 7.5% during after market hours.Press Release For further details see: Protagonist Therapeutics slumps 7.5% on rais...
Mohammed Haneefa Nizamudeen/iStock via Getty Images Protagonist Therapeutics ([[PTGX]] +16.7%) has surged after the company announced updated results from the ongoing Phase 2 study of rusfertide in the treatment of polycythemia vera ((PV)). The primary endpoint of the trial is the c...
Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera Rusfertide demonstrated sustained hematocrit control, reversal of iron deficiency, and a reduction in phlebotomies, for up to 18 months, in both high risk and...
Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021 PR Newswire NEWARK, Calif. , June 7, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq:...
Protagonist Therapeutics (PTGX) announced that the FDA has granted the Breakthrough Therapy Designation for its lead investigational candidate, rusfertide in the treatment of polycythemia vera ((PV)).The designation given to rusfertide in PV is for its development targeting the redu...
Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera Designation further validates registrational path for rusfertide in polycythemia vera and facilitates potentially expedited development and review PR Newswire ...
The first human subject has been dosed in Protagonist Therapeutics' ([[PTGX]] +3.1%) Phase 1 study of PN-232, a novel oral interleukin-23 receptor (IL-23R) antagonist peptide.The study is designed to determine the safety, tolerability, and pharmacokinetics of PN-232 in healthy volunteers...
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232 PR Newswire NEWARK, Calif. , May 24, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first hu...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...